CD274 and cancer: The MA31 cohort is a clinical trial of the Canadian Cancer Trials Group, conducted from January 17, 2008, through December 1, 2011, and was designed to evaluate the prognostic and predictive biomarker utility of pretreatment serum PD-L1 levels.